A common drug prescribed for diabetes, costing just two pence per tablet, may significantly lower the danger of prostate cancer. New research indicates a potential reduction in risk exceeding 30%. Metformin, a medication long established for managing blood sugar in individuals with type 2 diabetes, now presents a promising avenue for cancer prevention.
This disease, accountable for more than 12,000 fatalities each year within the United Kingdom, is a serious concern. Scientists posit that men facing a heightened risk of developing the illness could potentially gain substantial benefit from incorporating metformin into their treatment plan. The study highlights the versatility of this widely-used drug.
Millions of patients rely on metformin to control their blood glucose levels, and this latest investigation suggests a broader protective effect. Further research is planned to fully understand the mechanisms behind this observed reduction in cancer risk. Ultimately, the findings suggest that metformin could be a valuable tool in combating this prevalent and deadly disease, particularly for those individuals at greater vulnerability.
Topics: #risk #cancer #diabetes
A promising new study suggests that treatment for diabetes could lessen the chance of developing prostate cancer.